Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for recurrent primary central nervous system lymphoma
2015-005103-89Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Dec 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in primary central nervous system lymphoma (PCNSL), sponsored by Medical University of Vienna. Started Dec 2015; status: terminated.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2015-005103-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005103-89.